David: Last news item 4/18 posted here.
Contact Richard Salter at: Water25982@aol.com He has always responded promptly to my inquiries.
I don't know what news to expect on the fungicide. There could be news on it any day, for all I know. Below is their last news update. It seems people on this thread are not discussing the news. The stock does seem to hold strong between 5.75 and 6.125.
And I don't expect to hear any news on GBC-590 for awhile until they have analyzed how the patients are responding. However, Mr. Salter maybe able to give you some timeframes.
I remain long on IGGI.
andrew
CAMBRIDGE, Mass., April 18 (Reuter) - IGG International Inc
said Friday that two recently completed studies on its Elexa
product show the agricultural compound to be effective in
preventing fungal disease in tomato and seedlings of apple.
It said that in a field study at the University of
Pontifica in Chile, Elexa was tested on tomato plants and fruit
against a standard application of commercial chemicals.
In five weeks of application, results showed that plants
treated separately with Elexa and with the commercial chemicals
had 8.0 percent fungal damage, against 30 percent for untreated
plants.
In a greenhouse study on apple seedlings, IGG said that
Elexa combined with adjuvant -- an agent to improve
effectiveness -- showed a four-fold increase in protection.
It said control seedlings had, on average, more than 12
powdery mildew colonies for every leaf compared with three for
every leaf on seedlings treated with Elexa plus adjuvant.
The results of the trial on tomato will be used in a
pending application to the Chilean government for product
approval, it said. Pending approval, it said it could have
sales in Chile before the end of 1997.
On the apple seedlings study, it said it will expand
research into mature apple trees.
Bradley Carver, president of the company, said the tomato
study confirms earlier activity of the company involving core
carbohydrate-based technology.
At the same time, the results in the study on apple
seedlings will greatly expand the pontential application of
Elexa, he said.
IGG is a biotechnology company that develops complex
carbohydrate compounds, derived from naturally occurring
substances, for pharmcaceutical and agricultural applications. |
